Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research

Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial

Hany Siha, Debraj Das, Yuling Fu, Yinggan Zheng, Cynthia M. Westerhout, Robert F. Storey, Stefan James, Lars Wallentin and Paul W. Armstrong
CMAJ July 10, 2012 184 (10) 1135-1142; DOI: https://doi.org/10.1503/cmaj.111683
Hany Siha
From the University of Alberta (Siha, Das, Fu, Zheng, Westerhout, Armstrong), Edmonton, Alta.; the University of Sheffield (Storey), Sheffield, United Kingdom; and the Uppsala Clinical Research Center (James, Wallentin), Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debraj Das
From the University of Alberta (Siha, Das, Fu, Zheng, Westerhout, Armstrong), Edmonton, Alta.; the University of Sheffield (Storey), Sheffield, United Kingdom; and the Uppsala Clinical Research Center (James, Wallentin), Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuling Fu
From the University of Alberta (Siha, Das, Fu, Zheng, Westerhout, Armstrong), Edmonton, Alta.; the University of Sheffield (Storey), Sheffield, United Kingdom; and the Uppsala Clinical Research Center (James, Wallentin), Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yinggan Zheng
From the University of Alberta (Siha, Das, Fu, Zheng, Westerhout, Armstrong), Edmonton, Alta.; the University of Sheffield (Storey), Sheffield, United Kingdom; and the Uppsala Clinical Research Center (James, Wallentin), Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia M. Westerhout
From the University of Alberta (Siha, Das, Fu, Zheng, Westerhout, Armstrong), Edmonton, Alta.; the University of Sheffield (Storey), Sheffield, United Kingdom; and the Uppsala Clinical Research Center (James, Wallentin), Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert F. Storey
From the University of Alberta (Siha, Das, Fu, Zheng, Westerhout, Armstrong), Edmonton, Alta.; the University of Sheffield (Storey), Sheffield, United Kingdom; and the Uppsala Clinical Research Center (James, Wallentin), Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan James
From the University of Alberta (Siha, Das, Fu, Zheng, Westerhout, Armstrong), Edmonton, Alta.; the University of Sheffield (Storey), Sheffield, United Kingdom; and the Uppsala Clinical Research Center (James, Wallentin), Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Wallentin
From the University of Alberta (Siha, Das, Fu, Zheng, Westerhout, Armstrong), Edmonton, Alta.; the University of Sheffield (Storey), Sheffield, United Kingdom; and the Uppsala Clinical Research Center (James, Wallentin), Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul W. Armstrong
From the University of Alberta (Siha, Das, Fu, Zheng, Westerhout, Armstrong), Edmonton, Alta.; the University of Sheffield (Storey), Sheffield, United Kingdom; and the Uppsala Clinical Research Center (James, Wallentin), Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: paul.armstrong@ualberta.ca
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1:

    Selection of patients for inclusion in the study cohort. ECG = electrocardiogram, LBBB = left bundle branch block, MI = myocardial infarction, PCI = percutaneous coronary intervention, STEMI = ST-segment elevation myocardial infarction.

  • Figure 2:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2:

    Kaplan–Meier survival analysis of all-cause mortality within one year of randomization, by the presence of Q waves. p logrank < 0.001.

  • Figure 3:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3:

    Kaplan–Meier survival analysis of all-cause mortality within one year, by time from the onset of symptoms to percutaneous coronary intervention (PCI). p logrank = 0.03.

  • Figure 4:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4:

    Associations among baseline Q waves, time from symptom onset and mortality. (A) Association between all-cause mortality within one year and baseline Q waves and time from symptom onset to percutaneous coronary intervention (PCI). *Adjusted for age, systolic blood pressure, heart rate, Killip class, myocardial infarction location, Q waves and time from symptom onset. (B) Association between vascular mortality within one year and baseline Q waves and time from the onset of symptoms to PCI. †Adjusted for age, systolic blood pressure, heart rate, Killip class, myocardial infarction location, presence of Q waves and time from symptom onset.

Tables

  • Figures
    • View popup
    Table 1:

    Characteristics of the included patients, by time from the onset of symptoms to percutaneous coronary intervention and the presence of baseline Q waves

    Characteristic; median (25th, 75th percentile)*All patients
    n = 4341
    Time from the onset of symptoms to PCI
    ≤ 3 h
    n = 1052
    > 3 to ≤ 6 h
    n = 1675
    > 6 hr
    n = 1614
    No Q waves n = 2338Q waves n = 2003p valueNo Q waves n = 631Q waves n = 421p valueNo Q waves n = 942Q waves n = 733p valueNo Q waves n = 765Q waves n = 849p value
    Age, yr57 (51, 66)59 (52, 68)< 0.00156 (50, 64)58 (52, 66)0.0357 (51, 65)59 (53, 68)0.00159 (52, 68)60 (52, 69)0.09
    Female, %25.720.8< 0.00119.717.60.425.519.90.00730.923.1< 0.001
    Diabetes mellitus, %17.218.30.316.613.80.214.919.40.0120.419.60.7
    Hypertension, %55.956.70.648.752.30.255.657.30.4962.458.40.1
    Heart rate, beats per min74 (65, 84)78 (68, 90)< 0.00174 (65, 84)77 (66, 88)0.00274 (65, 83)79 (70, 90)< 0.00175 (65, 84)78 (68, 90)< 0.001
    Systolic blood pressure, mm Hg130 (120, 150)133 (120, 150)0.7130 (120, 147)135 (120, 150)0.1135 (120, 150)135 (120, 150)0.8132 (120, 150)130 (120, 150)0.6
    Killip class > 1, %5.08.3< 0.0014.17.10.034.16.70.026.710.30.01
    Creatinine clearance, mL/min89.9 (73.1, 105.9)85.8 (68.2, 105)0.00190.1 (74.5, 104.6)87.7 (68.2, 104.2)0.0690.1 (74.2, 107)84.7 (68.3, 104.6)0.00189.3 (70.2, 105.8)85.8 (68.2, 105.6)0.2
    Time from symptom onset to baseline ECG, hr2.3 (1.2, 4.2)3.0 (1.6, 6.0)< 0.0011.1 (0.7, 1.6)1.3 (0.8, 1.7)< 0.0012.5 (1.7, 3.3)2.8 (1.9, 3.6)< 0.0015.6 (3.1, 8.4)7 (4.5, 11.1)< 0.001
    Time from symptom onset to PCI, hr4.3 (2.9, 7.3)5.3 (3.3, 9.5)< 0.0012.3 (1.9, 2.7)2.4 (2.0, 2.7)0.14.2 (3.5, 4.9)4.3 (3.6, 5.1)0.0039.8 (7.4. 15.3)10.7 (7.8, 17.1)0.004
    • Note: ECG = electrocardiogram, PCI = percutaneous coronary intervention.

    • ↵* Unless otherwise stated.

    • View popup
    Table 2:

    Myocardial infarction location, electrocardiography metrics and cardiac biomarkers for the study population, by time from the onset of symptoms to percutaneous coronary intervention and the presence of baseline Q waves

    Characteristic; median (25th, 75th percentile)*All patients
    n = 4341
    Time from the onset of symptoms to PCI
    ≤ 3 h
    n = 1052
    > 3 to ≤ 6 h
    n = 1675
    > 6 h
    n = 1614
    No Q waves n = 2338Q waves n = 2003p valueNo Q waves n = 631Q waves n = 421p valueNo Q waves n = 942Q waves n = 733p valueNo Q waves n = 765Q waves n = 849p value
    Inferior MI, % of patients61.134.4< 0.00165.933.0< 0.00163.434.9< 0.00153.734.6< 0.001
    Baseline sum ST-segment elevation (∑ST-elevation), mm5 (2.5, 9)7.5 (4, 12.5)< 0.0016.5 (4, 11)9.5 (5.5, 16)< 0.0015.5 (3, 9.5)8.5 (5, 14)< 0.0013.5 (2, 6.5)5.5 (3, 10)< 0.001
    Baseline sum ST-segment deviation (∑ST-deviation), mm9.5 (5.5, 15.5)11 (6.5, 17.5)< 0.00111.5 (7, 17.5)13.5 (8.5, 21)< 0.00110.5 (6.5, 17)13 (8, 20)< 0.0017 (4, 11.5)9 (5, 13.5)< 0.001
    Sum ST-segment elevation resolution (∑ST-elevation) ≥ 50%, %79.066.5< 0.00186.876.9< 0.00182.472.5< 0.00167.556.3< 0.001
    Sum ST-segment deviation resolution (∑ST-deviation) ≥ 50%, %78.767.1< 0.00184.579.20.05085.173.8< 0.00165.355.4< 0.001
    Cardiac biomarkers
     Central troponin I ≥ 0.08 ng/mL at study entry, %84.591.8< 0.00170.280.10.00186.193.6< 0.00194.496.0< 0.05
     Peak local creatine kinase-MB, ratio of the ULNn = 1568
    5.1 (1.8, 12.7)
    n = 1379
    7.6 (2.6, 19.3)
    < 0.001n = 421
    4.4 (1.6, 12.1)
    n = 270
    9.2 (2.6, 21.3)
    < 0.001n = 659
    6 (2.1, 13.8)
    n = 520
    8.2 (2.7, 20.7)
    < 0.001n = 488
    3.9 (1.7, 10.2)
    n = 589
    6.7 (2.5, 16.7)
    < 0.001
     Peak local troponin I, ratio of the ULNn = 1280
    49.7 (5.3, 199.9)
    n = 1024
    100 (15.7, 374.5)
    < 0.001n = 375
    56.3 (4.1, 228)
    n = 242
    96.9 (12.2, 320.0)
    0.008n = 492
    57 (4.9, 215.1)
    n = 369
    103.4 (12.1, 434.8)
    < 0.001n = 413
    42.4 (8, 166.7)
    n = 413
    97.4 (28.8, 362.7)
    < 0.001
     Peak local troponin T, ratio of the ULNn = 740
    19.0 (2.9, 67.8)
    n = 620
    37.9 (8.7, 115.1)
    < 0.001n = 187
    22.3 (4.4, 82.7)
    n = 129
    39 (7.8, 116.5)
    0.068n = 309
    20 (2.7, 66.7)
    n = 222
    41.7 (9, 103.5)
    < 0.001n = 244
    12.8 (2.5, 60.5)
    n = 269
    31.7 (8.6, 116)
    < 0.001
    • Note: MI = myocardial infarction, PCI = percutaneous coronary intervention, ULN = upper limit of normal.

    • ↵* Sum ST-deviation is the elevation plus depression.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 184 (10)
CMAJ
Vol. 184, Issue 10
10 Jul 2012
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial
Hany Siha, Debraj Das, Yuling Fu, Yinggan Zheng, Cynthia M. Westerhout, Robert F. Storey, Stefan James, Lars Wallentin, Paul W. Armstrong
CMAJ Jul 2012, 184 (10) 1135-1142; DOI: 10.1503/cmaj.111683

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial
Hany Siha, Debraj Das, Yuling Fu, Yinggan Zheng, Cynthia M. Westerhout, Robert F. Storey, Stefan James, Lars Wallentin, Paul W. Armstrong
CMAJ Jul 2012, 184 (10) 1135-1142; DOI: 10.1503/cmaj.111683
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Interpretation
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • ST-elevation myocardial infarction: Is there time for Q waves?
  • Highlights
  • PubMed
  • Google Scholar

Cited By...

  • Q Waves at Presentation in Patients With ST-Segment-Elevation Myocardial Infarction: An Underappreciated Marker of Risk
  • Relationships Between Baseline Q Waves, Time From Symptom Onset, and Clinical Outcomes in ST-Segment-Elevation Myocardial Infarction Patients: Insights From the Vital Heart Response Registry
  • Biochemical Validation of Patient-Reported Symptom Onset Time in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
  • Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial
  • Prognostic value of the ECG
  • ST-elevation myocardial infarction: Is there time for Q waves?
  • Google Scholar

More in this TOC Section

  • Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19–related deaths among people with multimorbidity: a cohort study
  • Association between virtual primary care and emergency department use during the first year of the COVID-19 pandemic in Ontario, Canada
  • Survival and health care costs after inpatient elective surgery: comparison of patients with and without chronic obstructive pulmonary disease
Show more Research

Similar Articles

Collections

  • Topics
    • Cardiovascular medicine

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire